Paper41940985
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
Bruzzese A and 11 others. Ann Hematol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials. Papers, record 41940985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41940985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| fms-Like Tyrosine Kinase 3 | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Mutation | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Bayes Theorem | |
| Phenylurea Compounds | |
| Decitabine | |
| Treatment Outcome | |
| Sorafenib | |
| Gemtuzumab | |
| Staurosporine | |
| Protein Kinase Inhibitors | |
| Benzothiazoles | |
| Cytarabine | |
| Daunorubicin |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40097915 | A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. | Cancer | 2025 | https://conductscience.org/library/papers/40097915 | PubMed |
| 2 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 3 | 26549589 | Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26549589 | PubMed |
| 4 | 37647654 | Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. | Blood | 2023 | https://conductscience.org/library/papers/37647654 | PubMed |
| 5 | 38324741 | Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38324741 | PubMed |
| 6 | 33563904 | Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33563904 | PubMed |
| 7 | 40932876 | V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML. | Blood Neoplasia | 2025 | https://conductscience.org/library/papers/40932876 | PubMed |
| 8 | 39067406 | The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis. | Leuk Res | 2024 | https://conductscience.org/library/papers/39067406 | PubMed |
| 9 | 37604981 | Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. | Leukemia | 2023 | https://conductscience.org/library/papers/37604981 | PubMed |
| 10 | 31462531 | RoB 2: a revised tool for assessing risk of bias in randomised trials. | BMJ | 2019 | https://conductscience.org/library/papers/31462531 | PubMed |
| 11 | 15959528 | Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. | Leukemia | 2005 | https://conductscience.org/library/papers/15959528 | PubMed |
| 12 | 22482940 | Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. | Lancet | 2012 | https://conductscience.org/library/papers/22482940 | PubMed |
| 13 | 30076173 | Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. | Haematologica | 2019 | https://conductscience.org/library/papers/30076173 | PubMed |
| 14 | 38717861 | Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. | Blood | 2024 | https://conductscience.org/library/papers/38717861 | PubMed |
| 15 | 32241850 | Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | Haematologica | 2020 | https://conductscience.org/library/papers/32241850 | PubMed |
| 16 | 36497281 | Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36497281 | PubMed |
| 17 | 35732831 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732831 | PubMed |
| 18 | 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37116523 | PubMed |
| 19 | 38215358 | Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38215358 | PubMed |
| 20 | 36815379 | Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience. | Haematologica | 2023 | https://conductscience.org/library/papers/36815379 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42452347 | Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452347 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41940985
GET https://conductscience.org/api/papers/v1/41940985/references?page=2